secwatch.observer — SEC 8-K summary
======================================

Issuer:     OnKure Therapeutics, Inc. (OKUR)
CIK:        0001637715
Form:       8-K
Filed at:   2021-12-27T23:59:59+00:00
Accession:  0001193125-21-367001
Event type: leadership
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Reneo Pharma CBO Wendy Johnson to depart Dec 31, enters consulting agreement
----------------------------------------------------------------------------

- Wendy Johnson will cease as CBO on Dec 31, 2021; will serve as consultant for 18 months.
- Severance of $100k contingent on release of claims; continues base salary of $365k/yr until separation.
- Equity awards continue to vest during consulting period; full acceleration if Company terminates without cause before June 30, 2023.
- Cash consulting fee of $10k/month plus hourly rate for over 32 hours/month.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1637715/000119312521367001/0001193125-21-367001-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1637715/000119312521367001/d237276d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-21-367001

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer